{"id":4416,"date":"2018-06-15T10:23:02","date_gmt":"2018-06-15T14:23:02","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4416"},"modified":"2018-06-15T10:23:02","modified_gmt":"2018-06-15T14:23:02","slug":"kezar-life-sciences-inc-ipo-preview-kzr","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/kezar-life-sciences-inc-ipo-preview-kzr\/","title":{"rendered":"Kezar Life Sciences, Inc. #IPO Preview ($KZR)"},"content":{"rendered":"

\"KZR\"<\/a><\/p>\n

Company: Kezar Life Sciences, Inc.
\nSymbol: KZR
\nDescription: They are a clinical-stage biotechnology company, discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer.
\nTrade Date: 6\/21
\nShares: 4.67 million
\nPrice Range: $14.00-$16.00
\nUnderwriter(s): Jefferies, Cowen, Wells Fargo, William Blair
\nTerms Added: 6-8-18<\/p>\n

Link to Prospectus<\/a><\/strong><\/p>\n

Link to Retail Roadshow<\/a><\/strong><\/p>\n

Business<\/strong>:\u00a0They are a clinical-stage biotechnology company, discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer.\u00a0Their lead product candidate,\u00a0KZR-616,\u00a0a\u00a0first-in-class\u00a0selective immunoproteasome inhibitor, has completed testing in healthy volunteers and is now enrolling a Phase 1b\/2 clinical trial in lupus and lupus nephritis.\u00a0They believe that the immunoproteasome is a validated target for the treatment of a wide variety of autoimmune diseases given the compelling published activity seen with proteasome inhibitors administered to patients with severe autoimmune diseases. Their Phase 1a clinical trial results provide evidence that\u00a0KZR-616avoids the side effects caused by\u00a0non-selective\u00a0proteasome inhibitors, side effects that prevent them from being developed as a treatment in autoimmunity. Initial\u00a0top-line\u00a0results from the Phase 1b portion of their KZR-616 trial are expected in 2019, and they plan to initiate up to four additional trials in autoimmune diseases in 2019. They are also leveraging their protein secretion pathway platform to discover and develop small molecule therapies targeting cancer and immuno-oncology.<\/p>\n

\"Microsoft<\/a><\/p>\n

Insider Buying:<\/strong>\u00a0Certain of their\u00a0existing stockholders, including entities affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately $30\u00a0million in shares of their\u00a0common stock in this offering at the initial public offering price per share.<\/p>\n

Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n

IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n

Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique’s service.<\/p>\n

Indicate with confidence,\u00a0<\/b>SUBSCRIBE<\/b><\/a>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

Company: Kezar Life Sciences, Inc. Symbol: KZR Description: They are a clinical-stage biotechnology company, discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. Trade Date: 6\/21 Shares: 4.67 million Price Range: $14.00-$16.00 Underwriter(s): Jefferies, Cowen, Wells Fargo, William Blair Terms Added: 6-8-18 Link to Prospectus Link to Retail Roadshow[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[1],"tags":[],"class_list":["post-4416","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4416"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4416\/revisions"}],"predecessor-version":[{"id":4419,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4416\/revisions\/4419"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}